Reneo Pharmaceuticals, Inc.
RPHM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $1 | $0 |
| Gross Profit | $0 | -$1 | -$1 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $44 | $56 | $38 | $28 |
| G&A Expenses | $11 | $26 | $16 | $12 |
| SG&A Expenses | $11 | $26 | $16 | $12 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $1 | $0 | $0 |
| Operating Expenses | $54 | $83 | $54 | $40 |
| Operating Income | -$54 | -$83 | -$54 | -$40 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $6 | $2 | $0 |
| Pre-Tax Income | $0 | -$77 | -$52 | -$40 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $0 | -$77 | -$50 | -$40 |
| % Margin | – | – | – | – |
| EPS | 0 | -2.3 | -2.04 | -2.19 |
| % Growth | 100% | -12.7% | 6.8% | – |
| EPS Diluted | 0 | -2.3 | -2.04 | -2.19 |
| Weighted Avg Shares Out | 34 | 34 | 24 | 18 |
| Weighted Avg Shares Out Dil | 34 | 34 | 24 | 18 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $0 | $0 | $0 |
| Interest Expense | -$0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $1 | $0 |
| EBITDA | -$54 | -$82 | -$54 | -$40 |
| % Margin | – | – | – | – |